Fig. 2From: Clinical syndromes and treatment location predict utility of carbapenem sparing therapies in ceftriaxone-non-susceptible Escherichia coli bloodstream infection Potential carbapenem days spared.  DOT days of therapy. *Due to resistance, site of infection or contraindications. Individual bars represent the DOT per 100 patient-days of antimicrobial therapy and percentage of potential carbapenem days spared for each agent divided into setting of administration and empiric vs definitive therapyBack to article page